84773-29-5

Usage

Uses

Used in Pharmaceutical Industry:
(S)-(+)-2-(N-MethylaMino)-3-phenylpropanol is used as a key intermediate in the synthesis of cyclopropane-fused oxazepanones. These compounds exhibit antimycobacterial properties, making them valuable in the development of new drugs to combat tuberculosis and other mycobacterial infections.

Upstream product

• 2311-21-9 N-formyl-L-phenylalanine-methylester 
• 13200-85-6 N-formyl-L-phenylalanine 
• 63-91-2 L-phenylalanine 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 41844-71-7 methyl (S)-2-methoxycarbonylamino-3-phenyl-propionate 
• 2566-30-5 N-Methyl-L-phenylalanine 
• 63-91-2 L-phenylalanine 

Downstream Products

• 138850-42-7 3-(N,N')-<(S)-(1-benzylhydroxyethyl)methyl>aminocarbonylpyridine 
• 84694-30-4 2-phenyl>-3-methyl-4(S)-benzyloxazolidine 
• 157059-69-3 trans,trans-(S)-(-)-2-(N-methyl-N-cinnamoylamino)-3-phenylpropyl cinnamoate 
• 221134-09-4 (2S)-2-<3-butenoyl(methyl)amino>-3-phenylpropyl 3-butenoate 
• 221134-15-2 (2S)-2--3-phenylpropyl (E)-3-pentenoate 
• 221134-20-9 (2S)-2-methyl<(E)-4-phenyl-3-butenoyl>amino-3-phenylpropyl (E)-4-phenyl-3-butenoate 
• 573701-31-2 (S)-2-(N,N-benzylmethylamino)-3-phenylpropan-1-ol 
• 917599-26-9 (2S,4S)-2-(9-anthracenyl)-3-methyl-4-benzyl oxazolidine 
• 1146971-51-8 (S)-2-(methyl(prop-2-ynyl)amino)-3-phenylpropan-1-ol 
• 1146971-53-0 (S)-N-(1-fluoro-3-phenylpropan-2-yl)-N-methylprop-2-yn-1-amine 
• 1146972-97-5 (S)-N-(1-chloro-3-phenylpropan-2-yl)-N-methylprop-2-yn-1-amine 
• 1146971-54-1 N-[(2S)-1-[18F]fluoro-3-phenylpropan-2-yl]-N-methylprop-2-yn-1-amine 
• 138850-43-8 1-Methyl-3-(N,N')-<(S)-(1-benzylhydroxyethyl)methyl>aminocarbonylpyridinium iodide 
• 138850-40-5 1-Methyl-3-(N,N')-<(S)-(1-benzylhydroxyethyl)methyl>aminocarbonyl-1,4-dihydropyridine 

Relevant academic research and scientific papers

COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

This invention relates to novel compounds suitable as precursors for the preparation of certain 18F labelled positron emission tomography (PET) tracers. Furthermore, the invention relates to the preparation of such precursor molecules and to th

Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)

This invention relates to novel compounds suitable as precursors for the preparation of certain 18F labelled positron emission tomography (PET) tracers. Furthermore, the invention relates to the preparation of such precursor molecules and to th

Synthesis of three novel fluorine-18 labeled analogues of l -deprenyl for Positron Emission Tomography (PET) studies of Monoamine Oxidase B (MAO-B)

The aim in this project was to synthesize and to study fluorine-18 labeled analogues of l-deprenyl which bind selectively to the enzyme monoamine oxidase B (MAO-B). Three fluorinated l-deprenyl analogues have been generated in multistep organic syntheses. The most promising fluorine-18 compound N-[(2S)-1-[18F]fluoro-3-phenylpropan-2-yl]-N-methylprop-2-yn-1-amine (4c) was synthesized by a one-step fluorine-18 nucleophilic substitution reaction. Autoradiography on human brain tissue sections demonstrated specific binding for compound 4c to brain regions known to have a high content of MAO-B. In addition, the corresponding nonradioactive fluorine-19 compound (13) inhibited recombinant human MAO-B with an IC50 of 170.5 ±29 nM but did not inhibit recombinant human MAO-A (IC50 > 2000 nM), demonstrating its specificity. Biodistribution of 4c in mice showed high initial brain uptake leveling at 5.2 ±0.04%ID/g after 2 min post injection. In conclusion, compound 4c is a specific inhibitor of MAO-B with high initial brain uptake in mice and is, therefore, a candidate for further investigation in PET.

NOVEL PRECURSOR MOLECULES FOR F-18 LABELLED PET TRACERS

This invention relates to novel compounds suitable as precursors for the preparation of certain F-18 labeled positron emission tomography (PET) tracers. Furthermore, the invention relates to the preparation of such precursor molecules and to the preparation of PET tracers by F-18 labeling of such precursors.

COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS

This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds

N-Alkyl oxazolidines as stereocontrol elements in asymmetric Diels-Alder cycloadditions of 9-substituted anthracene derivatives

Chiral 9-oxazolidinyl anthracene derivatives have been prepared as single diastereoisomers by condensation of 9-anthraldehyde with the appropriate N-alkyl amino alcohol. Asymmetric Diels-Alder cycloadditions of these with N-methyl maleimide proceeds in go

Stereoselective synthesis of fused γ-lactams by intramolecular nitrone cycloaddition

A series of nitrones 5 joined by amides to olefines were prepared in situ from the related aldehydes with N-methylhydroxylamine. The nitrone added intramolecularly to the olefin, and the cycloadditions gave fused γ-lactams 6 stereoselectively. A stereocentre located in positron α to the nitronic functionality 13 completely controls the stereochemical course of the intramolecular cycloaddition, which exclusively affords compound 14 with simultaneous introduction of four stereocentres. The formation of this latter compound was also supported by PM3 calculations. Furthermore, simple heating of unsaturated oxine 17 led to compound 19 via intramolecular oxime olefin cycloaddition.

SYNTHESE D'AMINOPHOSPHINEPHOSPHINITES CHIRAUX. UTILISATION EN REDUCTION ASYMETRIQUE CATALYTIQUE

The chiral aminophosphinephosphinites ligands (AMPP) are directly synthesized from natural amino alcohols or by reduction of formyl esters of α-amino acids and PPh2Cl. Their cationic rhodium complexes have been found to be excellent catalysts for enantioselective hydrogenation of dehydroamino acids (ee ca. 86percent, yield ca. 100percent) for example.Asymmetric reduction of ketones can also be performed with the new alkyl AMPP* modified rhodium catalyst (ee 50percent).